The effect of human adipose-derived stem cells on lipopolysaccharide-induced acute respiratory distress syndrome in mice
Authors:
Open Access
- 1 November 2019
- journal article
- research article
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 7 (22) , 674
Abstract
Background: Acute respiratory distress syndrome (ARDS) is a type of acute respiratory failure in critically ill patients. Recently, several treatment modalities have been proposed for ARDS, but it still has a high mortality rate. In general, the role of mesenchymal stem cells (MSCs) in controlling inflammatory responses has been studied in various immune-associated diseases in humans and animals. However, only a few studies reported adipose-derived stem cells (ASCs), which are easier to isolate, are currently emerging as an attractive treatment option in ARDS. Therefore, in this study, we investigated the therapeutic effects of human ASCs and the regulation of inflammatory responses in an ARDS mouse model. Methods: In the ARDS model, lipopolysaccharide (LPS) (5 mg/kg) was administered via the intra tracheal injection method. The mice were divided into the following four groups: (I) saline + medium; (II) saline + ASCs (2×105); (III) LPS + medium; (IV) LPS + ASCs. The ARDS observation time was divided into short and long term. LPS administration increased the concentration of proinflammatory cytokines, which was a consistent systemic inflammatory response. Results: LPS/ASC group showed less neutrophil infiltration and less alveolar hemorrhage or congestion than did the LPS group. The lung injury scores of the LPS/ASC group were lower than those of the LPS group (3.8±0.9 vs. 6.8±1.1; P=0.03) at day 2. Compared to the LPS group, LPS/ASC group showed reduced collagen deposition around the vessels and fibrosis accompanied by alveolar septal or interstitial thickening and lower MPO levels than did the LPS group (453.2±26.2 vs. 670.2±65.9 pg/mL; PConclusions: ASC therapy can inhibit neutrophil recruitment, which shows trend of reducing short term lung injury (day 2) and affecting fibrosis in long term (day 7). Further studies are warranted to understand the mechanism and improve the therapeutic effect of ASCs.Keywords
This publication has 43 references indexed in Scilit:
- Efficacy of Mesenchymal Stromal Cell Therapy for Acute Lung Injury in Preclinical Animal Models: A Systematic ReviewPLOS ONE, 2016
- Human Mesenchymal Stem Cell Microvesicles for Treatment of Escherichia coli Endotoxin-Induced Acute Lung Injury in MiceStem Cells, 2014
- Allogeneic Human Mesenchymal Stem Cells Restore Epithelial Protein Permeability in Cultured Human Alveolar Type II Cells by Secretion of Angiopoietin-1*Journal of Biological Chemistry, 2010
- Monitoring Immune Dysfunctions in the Septic Patient: A New Skin for the Old CeremonyMolecular Medicine, 2008
- In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injuryThorax, 2007
- Duration and Intensity of NF-κB Activity Determine the Severity of Endotoxin-Induced Acute Lung InjuryThe Journal of Immunology, 2006
- Neutrophils and acute lung injuryCritical Care Medicine, 2003
- PULMONARY PATHOLOGY OF ACUTE RESPIRATORY DISTRESS SYNDROMEClinics in Chest Medicine, 2000
- Type III Procollagen Peptide in the Adult Respiratory Distress Syndrome: Association of Increased Peptide Levels in Bronchoalveolar Lavage Fluid with Increased Risk for DeathAnnals of Internal Medicine, 1995
- Granulocyte Depletion Prevents Tumor Necrosis Factor-mediated Acute Lung Injury in Guinea PigsAmerican Review of Respiratory Disease, 1988